264 related articles for article (PubMed ID: 28937974)
1. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; ; Russell SJ; Stewart AK
Blood Cancer J; 2017 Sep; 7(9):e612. PubMed ID: 28937974
[TBL] [Abstract][Full Text] [Related]
2. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
3. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
4. The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Nishijima A; Imai Y; Asada K; Ikeda Y; Karasaki T; Fujiwara K; Aburatani H; Kakimi K
Oncoimmunology; 2017; 6(8):e1338996. PubMed ID: 28920005
[TBL] [Abstract][Full Text] [Related]
5. Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma.
Dong C; Cesarano A; Bombaci G; Reiter JL; Yu CY; Wang Y; Jiang Z; Zaid MA; Huang K; Lu X; Walker BA; Perna F; Liu Y
Oncogene; 2021 Oct; 40(42):6130-6138. PubMed ID: 34504297
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
O'Donnell T; Christie EL; Ahuja A; Buros J; Aksoy BA; Bowtell DDL; Snyder A; Hammerbacher J
BMC Cancer; 2018 Jan; 18(1):87. PubMed ID: 29357823
[TBL] [Abstract][Full Text] [Related]
7. Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.
Nathanson T; Ahuja A; Rubinsteyn A; Aksoy BA; Hellmann MD; Miao D; Van Allen E; Merghoub T; Wolchok JD; Snyder A; Hammerbacher J
Cancer Immunol Res; 2017 Jan; 5(1):84-91. PubMed ID: 27956380
[TBL] [Abstract][Full Text] [Related]
8. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
Ren Y; Cherukuri Y; Wickland DP; Sarangi V; Tian S; Carter JM; Mansfield AS; Block MS; Sherman ME; Knutson KL; Lin Y; Asmann YW
Oncoimmunology; 2020; 9(1):1744947. PubMed ID: 32523802
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.
Goldsmith SR; Fiala MA; O'Neal J; Souroullas GP; Toama W; Vij R; Schroeder MA
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):744-750. PubMed ID: 31551170
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.
Liang H; Xu Y; Chen M; Zhao J; Zhong W; Liu X; Gao X; Li S; Li J; Guo C; Jia H; Wang M
Front Immunol; 2021; 12():749461. PubMed ID: 35356154
[TBL] [Abstract][Full Text] [Related]
11. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
[TBL] [Abstract][Full Text] [Related]
12. The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.
Wang Y; Xu J; Lan T; Zhou C; Liu P
Cancer Med; 2023 Dec; 12(24):21651-21665. PubMed ID: 37965778
[TBL] [Abstract][Full Text] [Related]
13. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
14. The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.
Lau TTY; Sefid Dashti ZJ; Titmuss E; Pender A; Topham JT; Bridgers J; Loree JM; Feng X; Pleasance ED; Renouf DJ; Schrader KA; Sun S; Ho C; Marra MA; Laskin J; Karsan A
J Mol Diagn; 2022 Jun; 24(6):609-618. PubMed ID: 35367630
[TBL] [Abstract][Full Text] [Related]
15.
Jian X; Xu L; Zhao J; Wang Y; Zhou W; Xie L
Mol Ther Nucleic Acids; 2022 Sep; 29():285-295. PubMed ID: 35950215
[TBL] [Abstract][Full Text] [Related]
16. Evolving neoantigen profiles in colorectal cancers with DNA repair defects.
Rospo G; Lorenzato A; Amirouchene-Angelozzi N; Magrì A; Cancelliere C; Corti G; Negrino C; Amodio V; Montone M; Bartolini A; Barault L; Novara L; Isella C; Medico E; Bertotti A; Trusolino L; Germano G; Di Nicolantonio F; Bardelli A
Genome Med; 2019 Jun; 11(1):42. PubMed ID: 31253177
[TBL] [Abstract][Full Text] [Related]
17. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Garofalo A; Sholl L; Reardon B; Taylor-Weiner A; Amin-Mansour A; Miao D; Liu D; Oliver N; MacConaill L; Ducar M; Rojas-Rudilla V; Giannakis M; Ghazani A; Gray S; Janne P; Garber J; Joffe S; Lindeman N; Wagle N; Garraway LA; Van Allen EM
Genome Med; 2016 Jul; 8(1):79. PubMed ID: 27460824
[TBL] [Abstract][Full Text] [Related]
18. Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.
Shukla SA; Howitt BE; Wu CJ; Konstantinopoulos PA
Gynecol Oncol Rep; 2017 Feb; 19():42-45. PubMed ID: 28070553
[TBL] [Abstract][Full Text] [Related]
19. Accounting for proximal variants improves neoantigen prediction.
Hundal J; Kiwala S; Feng YY; Liu CJ; Govindan R; Chapman WC; Uppaluri R; Swamidass SJ; Griffith OL; Mardis ER; Griffith M
Nat Genet; 2019 Jan; 51(1):175-179. PubMed ID: 30510237
[TBL] [Abstract][Full Text] [Related]
20. In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.
Ferrari V; Tarke A; Fields H; Ferrari L; Conley T; Ferrari F; Koşaloğlu-Yalçın Z; Sette A; Peters B; McCarthy CL; Bashey A; Tzachanis D; Ball ED; Tanaka TN; Bejar R; Lane TA; Vitiello A
Cytotherapy; 2021 Apr; 23(4):320-328. PubMed ID: 33262074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
